1. Clinical & Scientific Overview
Colchicine (TIP-MED-000123, Reference Code [7.21]) is classified under
Pain, Inflammation, Rheumatology & Gout Medicines (Ch 07) as a Microtubule Polymerisation & NLRP3 Inflammasome Inhibitor for Gout (Schedule H | NARROW THERAPEUTIC INDEX).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 07 [7.21], p. 89): Zygout (Zydus), Goutnil (Inga), Colchicindon (Zydus) — Strengths & Dosage Forms: Tablets: 0.5 mg (500 mcg)
Tablets: 0.5 mg (500 mcg)
3. Mechanism of Action & Pharmacodynamics
Microtubule Polymerisation & NLRP3 Inflammasome Inhibitor for Gout (Schedule H | NARROW THERAPEUTIC INDEX) acting on target receptor/enzyme pathways in Pain, Inflammation, Rheumatology & Gout Medicines (Ch 07): clinical efficacy is mediated via Microtubule Polymerisation & NLRP3 Inflammasome Inhibitor for Gout (Schedule H | NARROW THERAPEUTIC INDEX) for Acute gouty arthritis flare (especially when NSAIDs are contraindicated due to CKD, Heart Failure, HTN, or anticoagulation), flare prophylaxis during initiation of Allopurinol/Febuxostat, Familial Mediterranean Fever (FMF), and acute/recurrent pericarditis (ESC first-line).
4. Therapeutic Indications & Evidence-Supported Uses
- Acute gouty arthritis flare (especially when NSAIDs are contraindicated due to CKD, Heart Failure, HTN, or anticoagulation), flare prophylaxis during initiation of Allopurinol/Febuxostat, Familial Mediterranean Fever (FMF), and acute/recurrent pericarditis (ESC first-line)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: LOW-DOSE AGREE REGIMEN FOR ACUTE GOUT FLARE: 1.0 mg (two 0.5 mg tabs) stat at first sign of flare, followed 1 hour later by 0.5 mg (one tab) on Day 1 (Max 1.5 mg on Day 1!), then 0.5 mg OD–BD from Day 2 until flare resolves (Max total course 6 mg; wait >=3 days before repeating!). Flare Prophylaxis / Pericarditis: 0.5 mg PO OD–BD
Administration & Meal Timing: May be taken with or without food with water | Acute Flare: Stat + 1 hour later on Day 1, then OD–BD. Prophylaxis: Once or Twice Daily
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: eGFR 30–50 mL/min: Max 0.5 mg OD for prophylaxis and monitor closely; eGFR <30 mL/min: Avoid or limit prophylaxis to 0.5 mg every 2–3 days. Hepatic: Reduce dose by 50% in severe liver disease
Renal: eGFR 30–50 mL/min: Max 0.5 mg OD for prophylaxis and monitor closely; eGFR <30 mL/min: Avoid or limit prophylaxis to 0.5 mg every 2–3 days. Hepatic: Reduce dose by 50% in severe liver disease
Renal: eGFR 30–50 mL/min: Max 0.5 mg OD for prophylaxis and monitor closely; eGFR <30 mL/min: Avoid or limit prophylaxis to 0.5 mg every 2–3 days. Hepatic: Reduce dose by 50% in severe liver disease
7. Contraindications, Precautions & High-Risk Warnings
- NARROW THERAPEUTIC INDEX & FATAL OVERDOSE RISK: Never use the obsolete high-dose hourly regimen! Contraindicated in severe renal impairment (eGFR <30 mL/min) or hepatic impairment IF taking any P-gp or CYP3A4 inhibitor! Stop immediately if diarrhoea, vomiting, or muscle weakness develops
Key Clinical Precautions: Renal: eGFR 30–50 mL/min: Max 0.5 mg OD for prophylaxis and monitor closely; eGFR <30 mL/min: Avoid or limit prophylaxis to 0.5 mg every 2–3 days. Hepatic: Reduce dose by 50% in severe liver disease
8. Adverse Effects Profile
- Diarrhoea, nausea, vomiting, abdominal cramping (these are the earliest clinical warning signs of Colchicine toxicity — STOP drug immediately if they occur!)
- Fatal multi-organ Colchicine toxicity (gastroenteritis -> bone marrow aplasia/pancytopenia, rhabdomyolysis, neuromyopathy, alopecia, cardiogenic shock — NO specific antidote exists!)
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- FATAL INTERACTION WITH CYP3A4 & P-gp INHIBITORS: Clarithromycin, Erythromycin, Itraconazole, Ketoconazole, Cyclosporine, Verapamil, Diltiazem, Amiodarone, and Ritonavir increase Colchicine blood levels 200–300% and cause fatal pancytopenia/rhabdomyolysis! Additive myopathy with Statins and Fenofibrate
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: COUNTER SAFETY RULE: For an acute gout attack, take ONLY 2 tablets at the start and 1 tablet 1 hour later on Day 1 (never take tablets every hour!); STOP taking Zygout/Goutnil immediately at the very first sign of loose stools, nausea, or vomiting; never take with Clarithromycin or grapefruit juice
- Meal & Clock Timing Instruction: May be taken with or without food with water (Acute Flare: Stat + 1 hour later on Day 1, then OD–BD. Prophylaxis: Once or Twice Daily)
- Missed Dose Protocol: Skip if missed; never double dose
- Geriatric Dispensing Pearl: Halve prophylaxis dose (0.5 mg OD or alternate days) in older adults and verify Cockcroft–Gault CrCl & Statin/Diltiazem list
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Tablets: 0.5 mg (500 mcg)
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 07 [7.21] (p. 89)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [7.23] Leflunomide — Dihydroorotate Dehydrogenase (DHODH) Pyrimidine Synthesis Inhibit
- [7.24] Azathioprine & Mycophenolate Mofetil (MMF) — Purine Antimetabolite Immunosuppressants (Schedule H | NLEM 2022
- [7.25] Tofacitinib & Baricitinib (Oral JAK Inhibitors) — Targeted Synthetic Janus Kinase (JAK1/JAK3 & JAK1/JAK2) Inhibitor
- [7.26] Baclofen & Tizanidine Hydrochloride — GABA-B Receptor Agonist & Central Alpha-2 Adrenoceptor Agonist An
